# Kura Oncology, Inc.: financial statements, quarterly

KURA · Nasdaq · CIK 1422143 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kura.md) · [Financials](/companies/kura/financials.md) · [Filings](/companies/kura/filings.md) · [Insiders](/companies/kura/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kura/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [14.1](/filings/0001193125-26-219481.md) | [15.3](/filings/0001193125-26-346884.md) | [20.8](/filings/0001193125-25-263589.md) | [17.3 d](/filings/0001193125-26-092567.md) | [18.3](/filings/0001193125-26-219481.md) | [20.9](/filings/0001193125-26-346884.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.3](/filings/0001193125-26-219481.md) | [0.2](/filings/0001193125-26-346884.md) |
| Research and development | $m | [29.3](/filings/0000950170-24-123363.md) | [32.5 d](/filings/0001193125-26-092567.md) | [36.3](/filings/0000950170-25-061848.md) | [39.7](/filings/0000950170-25-105051.md) | [41.7](/filings/0001193125-25-263589.md) | [52.3 d](/filings/0001193125-26-092567.md) | [56.0](/filings/0001193125-26-219481.md) | [62.8](/filings/0001193125-26-346884.md) | [67.9](/filings/0001193125-25-263589.md) | [64.4 d](/filings/0001193125-26-092567.md) | [65.3](/filings/0001193125-26-219481.md) | [61.9](/filings/0001193125-26-346884.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | [22.8](/filings/0001193125-26-219481.md) | [25.2](/filings/0001193125-26-346884.md) | not reported | not reported | [31.6](/filings/0001193125-26-219481.md) | [31.8](/filings/0001193125-26-346884.md) |
| Operating income | $m | not reported | not reported | [(54.5)](/filings/0000950170-25-061848.md) | [(56.4)](/filings/0000950170-25-105051.md) | [(59.9)](/filings/0001193125-25-263589.md) | [(22.5) d](/filings/0001193125-26-092567.md) | [(64.7)](/filings/0001193125-26-219481.md) | [(72.7)](/filings/0001193125-26-346884.md) | [(80.0)](/filings/0001193125-25-263589.md) | [(86.3) d](/filings/0001193125-26-092567.md) | [(78.8)](/filings/0001193125-26-219481.md) | [(73.0)](/filings/0001193125-26-346884.md) |
| Interest expense | $m | [0.4](/filings/0000950170-23-058173.md) | [0.4 d](/filings/0000950170-24-021094.md) | [0.4](/filings/0000950170-24-052136.md) | [0.4](/filings/0000950170-24-093997.md) | [0.4](/filings/0001193125-25-263589.md) | [0.4 d](/filings/0001193125-26-092567.md) | [0.4](/filings/0001193125-26-219481.md) | [0.4](/filings/0001193125-26-346884.md) | [0.4](/filings/0001193125-25-263589.md) | [0.3 d](/filings/0001193125-26-092567.md) | [0.3](/filings/0001193125-26-219481.md) | [0.3](/filings/0001193125-26-346884.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.2](/filings/0001193125-26-219481.md) | [0.0 d](/filings/0001193125-26-346884.md) | [0.0 d](/filings/0001193125-25-263589.md) | [0.1 d](/filings/0001193125-26-092567.md) | [0.0](/filings/0001193125-26-219481.md) | [0.0](/filings/0001193125-26-346884.md) |
| Net income | $m | [(38.6)](/filings/0000950170-24-123363.md) | [(42.8) d](/filings/0001193125-26-092567.md) | [(49.5)](/filings/0001193125-25-263589.md) | [(50.8)](/filings/0001193125-25-263589.md) | [(54.4)](/filings/0001193125-25-263589.md) | [(19.2) d](/filings/0001193125-26-092567.md) | [(57.4)](/filings/0001193125-26-346884.md) | [(66.1)](/filings/0001193125-26-346884.md) | [(74.1)](/filings/0001193125-25-263589.md) | [(81.0) d](/filings/0001193125-26-092567.md) | [(73.3)](/filings/0001193125-26-346884.md) | [(68.3)](/filings/0001193125-26-346884.md) |
| Diluted EPS | $ per share | [(0.50)](/filings/0000950170-24-123363.md) | not reported | [(0.59)](/filings/0000950170-25-061848.md) | [(0.59)](/filings/0000950170-25-105051.md) | [(0.63)](/filings/0001193125-25-263589.md) | not reported | [(0.66)](/filings/0001193125-26-219481.md) | [(0.75)](/filings/0001193125-26-346884.md) | [(0.85)](/filings/0001193125-25-263589.md) | not reported | [(0.83)](/filings/0001193125-26-219481.md) | [(0.77)](/filings/0001193125-26-346884.md) |
| Basic EPS | $ per share | [(0.50)](/filings/0000950170-24-123363.md) | not reported | [(0.59)](/filings/0000950170-25-061848.md) | [(0.59)](/filings/0000950170-25-105051.md) | [(0.63)](/filings/0001193125-25-263589.md) | not reported | [(0.66)](/filings/0001193125-26-219481.md) | [(0.75)](/filings/0001193125-26-346884.md) | [(0.85)](/filings/0001193125-25-263589.md) | not reported | [(0.83)](/filings/0001193125-26-219481.md) | [(0.77)](/filings/0001193125-26-346884.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [28.7](/filings/0000950170-23-058173.md) | [37.3](/filings/0000950170-25-029975.md) | [41.5](/filings/0000950170-24-052136.md) | [45.2](/filings/0000950170-24-093997.md) | [49.5](/filings/0000950170-24-123363.md) | [224](/filings/0001193125-26-092567.md) | [51.3](/filings/0000950170-25-061848.md) | [81.9](/filings/0000950170-25-105051.md) | [95.3](/filings/0001193125-25-263589.md) | [149](/filings/0001193125-26-346884.md) | [39.1](/filings/0001193125-26-219481.md) | [70.2](/filings/0001193125-26-346884.md) |
| Current assets | $m | [460](/filings/0000950170-23-058173.md) | [432](/filings/0000950170-25-029975.md) | [538](/filings/0000950170-24-052136.md) | [500](/filings/0000950170-24-093997.md) | [463](/filings/0000950170-24-123363.md) | [745](/filings/0001193125-26-092567.md) | [724](/filings/0000950170-25-061848.md) | [660](/filings/0000950170-25-105051.md) | [621](/filings/0001193125-25-263589.md) | [709](/filings/0001193125-26-346884.md) | [624](/filings/0001193125-26-219481.md) | [559](/filings/0001193125-26-346884.md) |
| Total assets | $m | [474](/filings/0000950170-23-058173.md) | [449](/filings/0000950170-25-029975.md) | [554](/filings/0000950170-24-052136.md) | [515](/filings/0000950170-24-093997.md) | [479](/filings/0000950170-24-123363.md) | [760](/filings/0001193125-26-092567.md) | [744](/filings/0000950170-25-061848.md) | [682](/filings/0000950170-25-105051.md) | [649](/filings/0001193125-25-263589.md) | [738](/filings/0001193125-26-346884.md) | [653](/filings/0001193125-26-219481.md) | [588](/filings/0001193125-26-346884.md) |
| Current liabilities | $m | [27.5](/filings/0000950170-23-058173.md) | [35.3](/filings/0000950170-25-029975.md) | [32.3](/filings/0000950170-24-052136.md) | [33.5](/filings/0000950170-24-093997.md) | [40.4](/filings/0000950170-24-123363.md) | [78.7](/filings/0001193125-26-092567.md) | [89.8](/filings/0000950170-25-061848.md) | [107](/filings/0000950170-25-105051.md) | [121](/filings/0001193125-25-263589.md) | [117](/filings/0001193125-26-346884.md) | [101](/filings/0001193125-26-219481.md) | [118](/filings/0001193125-26-346884.md) |
| Total liabilities | $m | [43.8](/filings/0000950170-23-058173.md) | [51.7](/filings/0000950170-25-029975.md) | [48.8](/filings/0000950170-24-052136.md) | [49.0](/filings/0000950170-24-093997.md) | [55.1](/filings/0000950170-24-123363.md) | [347](/filings/0001193125-26-092567.md) | [379](/filings/0000950170-25-061848.md) | [377](/filings/0000950170-25-105051.md) | [407](/filings/0001193125-25-263589.md) | [564](/filings/0001193125-26-346884.md) | [545](/filings/0001193125-26-219481.md) | [539](/filings/0001193125-26-346884.md) |
| Long-term debt | $m | [9.3](/filings/0000950170-23-058173.md) | [9.3](/filings/0000950170-25-029975.md) | [9.4](/filings/0000950170-24-052136.md) | [8.6](/filings/0000950170-24-093997.md) | [7.8](/filings/0000950170-24-123363.md) | [6.9](/filings/0001193125-26-092567.md) | [7.7](/filings/0000950170-25-061848.md) | [6.5](/filings/0000950170-25-105051.md) | [5.3](/filings/0001193125-25-263589.md) | [9.7](/filings/0001193125-26-346884.md) | [9.7](/filings/0001193125-26-219481.md) | [5.6](/filings/0001193125-26-346884.md) |
| Current portion of debt | $m | not reported | not reported | not reported | [0.8](/filings/0000950170-24-093997.md) | [1.7](/filings/0000950170-24-123363.md) | [2.6](/filings/0001193125-26-092567.md) | [1.9](/filings/0000950170-25-061848.md) | [3.1](/filings/0000950170-25-105051.md) | [4.3](/filings/0001193125-25-263589.md) | [0.0](/filings/0001193125-26-346884.md) | not reported | [4.2](/filings/0001193125-26-346884.md) |
| Shareholders' equity | $m | [430](/filings/0000950170-24-123363.md) | [397](/filings/0001193125-26-092567.md) | [505](/filings/0001193125-25-263589.md) | [466](/filings/0001193125-25-263589.md) | [424](/filings/0001193125-25-263589.md) | [414](/filings/0001193125-26-346884.md) | [364](/filings/0001193125-26-346884.md) | [305](/filings/0001193125-26-346884.md) | [243](/filings/0001193125-25-263589.md) | [174](/filings/0001193125-26-346884.md) | [108](/filings/0001193125-26-346884.md) | [48.4](/filings/0001193125-26-346884.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(29.0) d](/filings/0000950170-24-123363.md) | [(34.3) d](/filings/0001193125-26-092567.md) | [(48.8)](/filings/0000950170-25-061848.md) | [(42.5) d](/filings/0000950170-25-105051.md) | [(43.4) d](/filings/0001193125-25-263589.md) | [269 d](/filings/0001193125-26-092567.md) | [(71.9)](/filings/0001193125-26-219481.md) | [(28.8) d](/filings/0001193125-26-346884.md) | [(80.6) d](/filings/0001193125-25-263589.md) | [117 d](/filings/0001193125-26-092567.md) | [(85.9)](/filings/0001193125-26-219481.md) | [(62.5) d](/filings/0001193125-26-346884.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-123363.md) | [0.0 d](/filings/0001193125-26-092567.md) | [0.1](/filings/0000950170-25-061848.md) | [0.0 d](/filings/0000950170-25-105051.md) | [0.0 d](/filings/0001193125-25-263589.md) | [0.4 d](/filings/0001193125-26-092567.md) | [0.3](/filings/0001193125-26-219481.md) | [1.5 d](/filings/0001193125-26-346884.md) | [2.6 d](/filings/0001193125-25-263589.md) | [2.3 d](/filings/0001193125-26-092567.md) | [0.1](/filings/0001193125-26-219481.md) | [0.7 d](/filings/0001193125-26-346884.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [66.9](/filings/0000950170-23-058173.md) | [68.4](/filings/0000950170-24-052136.md) | [69.8](/filings/0000950170-24-093997.md) | [77.2](/filings/0000950170-24-123363.md) | [83.9](/filings/0000950170-25-061848.md) | [86.6](/filings/0000950170-25-105051.md) | [87.0](/filings/0001193125-25-263589.md) | [87.4](/filings/0001193125-26-219481.md) | [87.6](/filings/0001193125-26-346884.md) | [87.6](/filings/0001193125-25-263589.md) | [88.6](/filings/0001193125-26-219481.md) | [88.9](/filings/0001193125-26-346884.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 88,960,619 at 2026-08-07, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-346884.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.